This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van Baelen, K.
Right arrow Articles by Stuyver, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Baelen, K.
Right arrow Articles by Stuyver, L. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2009, p. 2185-2188, Vol. 53, No. 5
0066-4804/09/$08.00+0     doi:10.1128/AAC.01650-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Susceptibility of Human Immunodeficiency Virus Type 1 to the Maturation Inhibitor Bevirimat Is Modulated by Baseline Polymorphisms in Gag Spacer Peptide 1 {triangledown}

Kurt Van Baelen,1* Karl Salzwedel,2 Evelien Rondelez,1 Veerle Van Eygen,1 Stephanie De Vos,1 Ann Verheyen,1 Kim Steegen,1 Yvan Verlinden,1 Graham P. Allaway,2 and Lieven J. Stuyver1

Virco BVBA, Generaal De Wittelaan L11 B3, 2800 Mechelen, Belgium,1 Panacos Pharmaceuticals Inc., 209 Perry Parkway, Gaithersburg, Maryland 208772

Received 16 December 2008/ Returned for modification 21 January 2009/ Accepted 30 January 2009

In this study, we evaluated baseline susceptibility to bevirimat (BVM), the first in a new class of antiretroviral agents, maturation inhibitors. We evaluated susceptibility to BVM by complete gag genotypic and phenotypic testing of 20 patient-derived human immunodeficiency virus type 1 isolates and 20 site-directed mutants. We found that reduced BVM susceptibility was associated with naturally occurring polymorphisms at positions 6, 7, and 8 in Gag spacer peptide 1.

* Corresponding author. Mailing address: Virco BVBA, Generaal De Wittelaan L11 B3, 2800 Mechelen, Belgium. Phone: 32 15 461 626. Fax: 32 15 285 634. E-mail: kvbaele1{at}its.jnj.com

{triangledown} Published ahead of print on 17 February 2009.

Antimicrobial Agents and Chemotherapy, May 2009, p. 2185-2188, Vol. 53, No. 5
0066-4804/09/$08.00+0     doi:10.1128/AAC.01650-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Blair, W. S., Cao, J., Fok-Seang, J., Griffin, P., Isaacson, J., Jackson, R. L., Murray, E., Patick, A. K., Peng, Q., Perros, M., Pickford, C., Wu, H., Butler, S. L. (2009). New Small-Molecule Inhibitor Class Targeting Human Immunodeficiency Virus Type 1 Virion Maturation. Antimicrob. Agents Chemother. 53: 5080-5087 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»